At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 27 enrolled
Drug / intervention
Carfilzomib +2 moredrug
Likely dose
Carfilzomib 20mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase Ib/IIa Study of Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell Lymphomas
In Brief
A Phase 2 clinical trial evaluating Carfilzomib, Romidepsin, and 1 other intervention for T-cell Lymphomas and Relapsed or Refractory. Completed, enrolled 27 participants across 6 sites.
Detailed Summary
This is an open label phase Ib/IIa study of patients with relapsed/refractory B- and T-cell lymphomas who are treated with carfilzomib, lenalidomide and romidepsin.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsT-cell Lymphomas, Relapsed or Refractory
CountriesUnited States
CollaboratorsUniversity of Nebraska
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartJan 2015
First PostedJan 2015
Primary CompletionJan 2023
TodayJul 2026
First PostedJan 19, 2015
Enrollment StartJan 2, 2015
Primary CompletionJan 11, 2023
TodayJul 2, 2026
Enrollment to primary: 8.0 yearsPosted 11.5 years ago
Interventions
Carfilzomibdrug
The initial dose of carfilzomib (cycle 1, day 1) given to any patient must be 20mg/m2 .
Romidepsindrug
Lenalidomidedrug